Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis.

ABSTRACT:

Background

Vedolizumab is a humanized monoclonal antibody targeting the α₄β₇ integrin used for the treatment of ulcerative colitis. Few biomarkers related to vedolizumab response have been identified. The aim of this work was to assess whether baseline circulating CD4⁺ and CD8⁺ memory T-lymphocyte subpopulations could help to identify patients with response to vedolizumab treatment in ulcerative colitis.

Methods

Prospective pilot study in 15 patients with active ulcerative colitis and previous failure to anti-TNFα starting vedolizumab treatment. Peripheral blood samples were obtained before the first dose of vedolizumab and at week 6 and 14 of treatment. Clinical remission was defined as a Mayo Clinic partial score of ≤2 points wit

SUBMITTER: Gonzalez-Vivo M 

PROVIDER: S-EPMC9240758 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature